

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 May 2009 (07.05.2009)

PCT

(10) International Publication Number
WO 2009/058076 A1

(51) International Patent Classification:

C07D 241/24 (2006.01)	A61P 11/00 (2006.01)
A61K 31/4965 (2006.01)	A61P 19/00 (2006.01)
A61K 31/497 (2006.01)	C07D 401/04 (2006.01)
A61K 31/506 (2006.01)	C07D 403/04 (2006.01)
A61P 1/04 (2006.01)	

(SE). LÖNN, Hans [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). LUNDKVIST, Michael [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).

(74) Agent: ASTRAZENECA AB; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2008/051220

(22) International Filing Date: 29 October 2008 (29.10.2008)

(25) Filing Language: English

(26) Publication Language: English


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE



(57) **Abstract:** The invention provides compounds of formula (I) wherein R¹, R³, R⁴, R⁵, R¹⁴, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

WO 2009/058076 A1

2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

Field of the Invention

The present invention relates to 2-pyrazinone derivatives, processes for their preparation, 5 pharmaceutical compositions containing them and their use in therapy.

Background of the Invention

Elastases are possibly the most destructive enzymes in the body, having the ability to degrade virtually all connective tissue components. The uncontrolled proteolytic 10 degradation by elastases has been implicated in a number of pathological conditions.

Human neutrophil elastase (hNE), a member of the chymotrypsin superfamily of serine proteases is a 33-KDa enzyme stored in the azurophilic granules of the neutrophils. In neutrophils the concentration of NE exceeded 5 mM and its total cellular amount has been estimated to be up to 3 pg. Upon activation, NE is rapidly released from the granules into 15 the extracellular space with some portion remaining bound to neutrophil plasma membrane (See Kawabat et al. 2002, Eur. J. Pharmacol. 451, 1-10). The main intracellular physiological function of NE is degradation of foreign organic molecules phagocytosed by neutrophils, whereas the main target for extracellular elastase is elastin (Janoff and Scherer, 1968, J. Exp. Med. 128, 1137-1155). NE is unique, as compared to other proteases 20 (for example, proteinase 3) in that it has the ability to degrade almost all extracellular matrix and key plasma proteins (See Kawabat et al., 2002, Eur. J. Pharmacol. 451, 1-10). It degrades a wide range of extracellular matrix proteins such as elastin, Type 3 and type 4 collagens, laminin, fibronectin, cytokines, etc. (Ohbayashi, H., 2002, Expert Opin. Investig. Drugs, 11, 965-980). NE is a major common mediator of many pathological 25 changes seen in chronic lung disease including epithelial damage (Stockley, R.A. 1994, Am. J. Resp. Crit. Care Med. 150, 109-113).

The destructive role of NE was solidified almost 40 years ago when Laurell and Eriksson reported an association of chronic airflow obstruction and emphysema with deficiency of 30 serum α_1 -antitrypsin (Laurell and Eriksson, 1963, Scand. J. Clin. Invest. 15, 132-140).

Subsequently it was determined that α_1 -antitrypsin is the most important endogenous inhibitor of human NE. The imbalance between human NE and endogenous antiprotease is

believed to cause excess human NE in pulmonary tissues which is considered as a major pathogenic factor in chronic obstructive pulmonary disease (COPD). The excessive human NE shows a prominent destructive profile and actively takes part in destroying the normal pulmonary structures, followed by the irreversible enlargement of the respiratory airspaces,
5 as seen mainly in emphysema. There is an increase in neutrophil recruitment into the lungs which is associated with increased lung elastase burden and emphysema in α_1 -proteinase inhibitor-deficient mice (Cavarra et al., 1996, Lab. Invest. 75, 273-280). Individuals with higher levels of the NE- α_1 protease inhibitor complex in bronchoalveolar lavage fluid show significantly accelerated decline in lung functions compared to those with lower levels
10 (Betsuyaku et al. 2000, Respiration, 67, 261-267). Instillation of human NE via the trachea in rats causes lung haemorrhage, neutrophil accumulation during acute phase and emphysematous changes during chronic phase (Karaki et al., 2002, Am. J. Resp. Crit. Care Med., 166, 496-500). Studies have shown that the acute phase of pulmonary emphysema and pulmonary haemorrhage caused by NE in hamsters can be inhibited by pre-treatment
15 with inhibitors of NE (Fujie et al.,1999, Inflamm. Res. 48, 160-167).

Neutrophil-predominant airway inflammation and mucus obstruction of the airways are major pathologic features of COPD, including cystic fibrosis and chronic bronchitis. NE impairs mucin production, leading to mucus obstruction of the airways. NE is reported to
20 increase the expression of major respiratory mucin gene, MUC5AC (Fischer, B.M & Voynow, 2002, Am. J. Respir. Cell Biol., 26, 447-452). Aerosol administration of NE to guinea pigs produces extensive epithelial damage within 20 minutes of contact (Suzuki et al., 1996, Am. J. Resp. Crit. Care Med., 153, 1405-1411). Furthermore NE reduces the ciliary beat frequency of human respiratory epithelium *in vitro* (Smallman et al., 1984, Thorax, 39, 663-667) which is consistent with the reduced mucociliary clearance that is seen in COPD patients (Currie et al., 1984, Thorax, 42, 126-130). The instillation of NE into the airways leads to mucus gland hyperplasia in hamsters (Lucey et al., 1985, Am. Resp. Crit. Care Med., 132, 362-366). A role for NE is also implicated in mucus hypersecretion in asthma. In an allergen sensitised guinea pig acute asthma model an
25 inhibitor of NE prevented goblet cell degranulation and mucus hypersecretion (Nadel et al., 1999, Eur. Resp. J., 13, 190-196).

NE has been also shown to play a role in the pathogenesis of pulmonary fibrosis.

NE: α_1 -protease inhibitor complex is increased in serum of patients with pulmonary fibrosis, which correlates with the clinical parameters in these patients (Yamanouchi et al., 1998, Eur. Resp. J. 11, 120-125). In a murine model of human pulmonary fibrosis, a NE inhibitor reduced bleomycin-induced pulmonary fibrosis (Taooka et al., 1997, Am. J. Resp. Crit. Care Med., 156, 260-265). Furthermore investigators have shown that NE deficient mice are resistant to bleomycin-induced pulmonary fibrosis (Dunsmore et al., 2001, Chest, 120, 35S-36S). Plasma NE level was found to be elevated in patients who progressed to ARDS implicating the importance of NE in early ARDS disease pathogenesis. (Donnelly et al., 1995, Am. J. Res. Crit. Care Med., 151, 428-1433). The antiproteases and NE complexed with antiprotease are increased in lung cancer area (Marchandise et al., 1989, Eur. Resp. J. 2, 623-629). Recent studies have shown that polymorphism in the promoter region of the NE gene are associated with lung cancer development (Taniguchi et al., 2002, Clin. Cancer Res., 8, 1115-1120).

Acute lung injury caused by endotoxin in experimental animals is associated with elevated levels of NE (Kawabata, et al., 1999, Am. J. Resp. Crit. Care, 161, 2013-2018). Acute lung inflammation caused by intratracheal injection of lipopolysaccharide in mice has been shown to elevate the NE activity in bronchoalveolar lavage fluid which is significantly inhibited by a NE inhibitor (Fujie et al., 1999, Eur. J. Pharmacol., 374, 117-125; Yasui, et al., 1995, Eur. Resp. J., 8, 1293-1299). NE also plays an important role in the neutrophil-induced increase of pulmonary microvascular permeability observed in a model of acute lung injury caused by tumour necrosis factor α (TNF α) and phorbol myristate acetate (PMA) in isolated perfused rabbit lungs (Miyazaki et al., 1998, Am. J. Respir. Crit. Care Med., 157, 89-94).

A role for NE has also been suggested in monocrotaline-induced pulmonary vascular wall thickening and cardiac hypertrophy (Molteni et al., 1989, Biochemical Pharmacol. 38, 2411-2419). Serine elastase inhibitor reverses the monocrotaline-induced pulmonary hypertension and remodelling in rat pulmonary arteries (Cowan et al., 2000, Nature Medicine, 6, 698-702). Recent studies have shown that serine elastase, that is, NE or vascular elastase are important in cigarette smoke-induced muscularisation of small


pulmonary arteries in guinea pigs (Wright et al., 2002, Am. J. Respir. Crit. Care Med., 166, 954-960).

NE plays a key role in experimental cerebral ischemic damage (Shimakura et al., 2000, 5 Brain Research, 858, 55-60), ischemia-reperfusion lung injury (Kishima et al., 1998, Ann. Thorac. Surg. 65, 913-918) and myocardial ischemia in rat heart (Tiefenbacher et al., 1997, Eur. J. Physiol., 433, 563-570). Human NE levels in plasma are significantly increased above normal in inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis (Adeyemi et al., 1985, Gut, 26, 1306-1311). In addition NE has also been assumed 10 to be involved in the pathogenesis of rheumatoid arthritis (Adeyemi et al., 1986, Rheumatol. Int., 6, 57). The development of collagen induced arthritis in mice is suppressed by a NE inhibitor (Kakimoto et al., 1995, Cellular Immunol. 165, 26-32).

Thus, human NE is known as one of the most destructive serine proteases and has been 15 implicated in a variety of inflammatory diseases. The important endogenous inhibitor of human NE is α_1 -antitrypsin. The imbalance between human NE and antiprotease is believed to give rise to an excess of human NE resulting in uncontrolled tissue destruction. The protease/ antiprotease balance may be upset by a decreased availability of α_1 -antitrypsin either through inactivation by oxidants such as cigarette smoke, or as a 20 result of genetic inability to produce sufficient serum levels. Human NE has been implicated in the promotion or exacerbation of a number of diseases such as pulmonary emphysema, pulmonary fibrosis, adult respiratory distress syndrome (ARDS), ischemia reperfusion injury, rheumatoid arthritis and pulmonary hypertension.

25 Disclosure of the Invention

In accordance with the present invention, there is therefore provided a compound of formula (I)



(I)

wherein

R^1 represents hydrogen or C_1 - C_6 alkyl;

5

W represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; and wherein the phenyl or heteroaromatic ring is optionally substituted by at least one substituent selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, CN, OH, NO_2 , C_1 - C_3 alkyl substituted by one or more F atoms, C_1 - C_3 alkoxy substituted by one or more F atoms, $NR^{10}R^{11}$, $C\equiv CR^{15}$, $CONR^{16}R^{17}$, CHO, C_2 - C_4 alkanoyl, $S(O)_xR^{18}$ and OSO_2R^{19} ;

R^{14} represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted in the 4- (para) position with F, Cl, CN or CF_3 ;

R^{10} , R^{11} , R^{12} and R^{13} independently represent H, C_1 - C_6 alkyl, formyl or C_2 - C_6 alkanoyl; or the group $-NR^{10}R^{11}$ or $-NR^{12}R^{13}$ together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR^{26} ;

R^{15} and R^{30} independently represent H, C_1 - C_3 alkyl or $Si(CH_3)_3$;

R^{18} , R^{19} , R^{33} and R^{34} independently represent H or C₁-C₃ alkyl; said alkyl being optionally substituted by one or more F atoms;

R^3 represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said ring being optionally substituted with at least one substituent selected from halogen, C₁-C₆ alkyl, cyano, C₁-C₆ alkoxy, nitro, methylcarbonyl, NR³⁵R³⁶, C₁-C₃ alkyl substituted by one or more F atoms or C₁-C₃ alkoxy substituted by one or more F atoms;

R^{35} and R^{36} independently represent H or C₁-C₃ alkyl; said alkyl being optionally further substituted by one or more F atoms;

R^4 represents hydrogen or C₁-C₆ alkyl optionally substituted with at least one substituent selected from fluoro, hydroxyl and C₁-C₆ alkoxy;

X represents a single bond, O, NR²⁴ or a group -C₁-C₆ alkylene-Y-, wherein Y represents a single bond, oxygen atom, NR²⁴ or S(O)_w; and said alkylene being optionally further substituted by OH, halogen, CN, NR³⁷R³⁸, C₁-C₃ alkoxy, CONR³⁹R⁴⁰, CO₂R⁶⁶, SO₂R⁴¹ and SO₂NR⁴²R⁴³;

R^4 and X are joined together such that the group -NR⁴X together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR⁴⁴; said ring being optionally substituted by C₁-C₆ alkyl or NR⁴⁵R⁴⁶; said alkyl being optionally further substituted by OH;

R^5 represents a monocyclic ring system selected from

- phenoxy,

- ii) phenyl,
- iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur,
- iv) a saturated or partially unsaturated C₃-C₆ cycloalkyl ring, or
- 5 v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at least one ring heteroatom selected from oxygen, S(O)_r and NR²⁰, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group,

or R⁵ represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)_t or C₁-C₆ alkylene optionally comprising one or more internal or terminal heteroatoms selected from oxygen, sulphur and NR²⁷ and being optionally substituted by at least one substituent selected from hydroxyl, oxo and C₁-C₆ alkoxy,

the monocyclic or bicyclic ring system being optionally substituted by at least one substituent selected from oxygen, CN, OH, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, NR⁴⁷R⁴⁸, NO₂, OSO₂R⁴⁹, CO₂R⁵⁰, C(=NH)NH₂, C(O)NR⁵¹R⁵², C(S)NR⁵³R⁵⁴, SC(=NH)NH₂, 20 NR⁵⁵C(=NH)NH₂, S(O)_vR²¹, SO₂NR⁵⁶R⁵⁷, C₁-C₃ alkoxy substituted by one or more F atoms and C₁-C₃ alkyl substituted by SO₂R⁵⁸ or by one or more F atoms; said C₁-C₆ alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio and -C(O)NR²²R²³;

25 or R⁵ may also represent H;

R^{20} represents hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylcarbonyl or C₁-C₆ alkoxy carbonyl;

5 R^{21} represents hydrogen, C₁-C₆ alkyl or C₃-C₈ cycloalkyl; said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, C₁-C₃ alkoxy and CONR⁵⁹R⁶⁰;

10 R^{37} and R^{38} independently represent H, C₁-C₆ alkyl, formyl or C₂-C₆ alkanoyl;

15 R^{47} and R^{48} independently represent H, C₁-C₆ alkyl, formyl, C₂-C₆ alkanoyl, S(O)_qR⁶¹ or SO₂NR⁶²R⁶³; said alkyl group being optionally further substituted by halogen, CN, C₁-C₄ alkoxy or CONR⁶⁴R⁶⁵;

20 R^{41} and R^{61} independently represent H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

15 p is 0, 1 or 2;

q is 0, 1 or 2;

r is 0, 1 or 2;

t is 0, 1 or 2;

20 w is 0, 1 or 2;

x is 0, 1 or 2;

v is 0, 1 or 2;

25 R^{16} , R^{17} , R^{22} , R^{23} , R^{24} , R^{26} , R^{27} , R^{31} , R^{32} , R^{39} , R^{40} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} ,

25 R^{49} , R^{50} , R^{51} , R^{52} , R^{53} , R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{60} , R^{62} , R^{63} , R^{64} , R^{65} and R^{66}

each independently represent hydrogen or C₁-C₆ alkyl;

or a pharmaceutically acceptable salt thereof.

In the context of the present specification, unless otherwise stated, an alkyl, alkenyl or alkynyl substituent group or an alkyl moiety in a substituent group may be linear or branched. Similarly, an alkylene group may be linear or branched.

5

R^1 represents hydrogen or C₁-C₆ alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).

In one embodiment of the invention, R^1 represents a C₁-C₄ or C₁-C₂ alkyl group, in particular a methyl group.

10 W represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; and wherein the phenyl or heteroaromatic ring is optionally substituted by at least one substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C₁-C₄ alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl), C₁-C₄ alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy), cyano, OH, NO₂, C₁-C₃ alkyl substituted by one or more F atoms (e.g. CH₂F, CHF₂, CF₃, CH₂CH₂F, CH₂CF₃, CF₂CF₃, CH(CF₃)₂ and CH₂CH₂CF₃), C₁-C₃ alkoxy substituted by one or more F atoms (e.g. OCH₂F, OCHF₂, OCF₃, OCH₂CH₂F, OCH₂CF₃, OCF₂CF₃, OCH(CF₃)₂ and OCH₂CH₂CF₃), NR¹⁰R¹¹, C≡CR¹⁵-C(O)NR¹⁶R¹⁷, CHO, C₂-C₄ alkanoyl (e.g. methylcarbonyl (acetyl), ethylcarbonyl, n-propylcarbonyl or isopropylcarbonyl), -S(O)_xR¹⁸, and OSO₂R¹⁹.

15 In one embodiment, the group R¹⁴ and the pyrazinone ring are bonded to the phenyl or 6-membered heteroaromatic ring W in a 1,2-relationship.

20 In one embodiment, W represents a phenyl ring, especially an unsubstituted phenyl ring.

In one embodiment, W represents a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms, especially an unsubstituted 6-membered heteroaromatic ring. In one embodiment, W represents a pyrazinyl, pyrimidinyl or pyridinyl ring, especially an unsubstituted pyrazinyl, pyrimidinyl or pyridinyl ring.

5

R^{14} represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 (e.g. one, two or three) ring nitrogen atoms; said ring being optionally substituted in the 4- (para) position with F, Cl, CN or CF_3 .

10 Examples of a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms include pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl. A preferred heteroaromatic ring system for R^{14} is pyridinyl.

15 In an embodiment of the invention, R^{14} represents phenyl or pyridinyl; said ring being optionally substituted in the 4- (para) position with F, Cl, CN or CF_3 .

In an embodiment of the invention, R^{14} represents phenyl or pyridinyl; said ring being 4- (para) substituted with F, Cl or CN.

20 R^3 represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 (e.g. one, two or three) heteroatoms independently selected from O, S and N; said ring being optionally substituted with at least one (e.g. one, two, three or four) substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C_1 - C_6 alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), cyano, C_1 - C_6 alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy), nitro, methylcarbonyl, NR^{35} R^{36} , C_1 - C_3 alkyl substituted by one or more F atoms (e.g. CH_2F , CHF_2 , CF_3 , CH_2CH_2F , CH_2CF_3 , CF_2CF_3 , $CH(CF_3)_2$ and

25

$\text{CH}_2\text{CH}_2\text{CF}_3$) and $\text{C}_1\text{-C}_3$ alkoxy substituted by one or more F atoms (e.g. OCH_2F , OCHF_2 , OCF_3 , $\text{OCH}_2\text{CH}_2\text{F}$, OCH_2CF_3 , OCF_2CF_3 , $\text{OCH}(\text{CF}_3)_2$ and $\text{OCH}_2\text{CH}_2\text{CF}_3$).

In one embodiment, R^3 represents a phenyl or pyridinyl ring substituted with at least one substituent (e.g. one, two or three substituents) independently selected from halogen, 5 cyano, nitro, methyl, trifluoromethyl and methylcarbonyl.

In one embodiment, R^3 represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro and trifluoromethyl.

10

In another embodiment, R^3 represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine and trifluoromethyl.

15

In still another embodiment, R^3 represents a phenyl group substituted with a trifluoromethyl substituent (preferably in the meta position).

In still another embodiment, R^3 represents a phenyl group substituted in the meta position with Br , Cl , CF_3 or CN .

25

R^4 represents hydrogen or $\text{C}_1\text{-C}_6$ alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted with at least one substituent (e.g. one or two substituents) independently selected from fluoro, hydroxyl and $\text{C}_1\text{-C}_6$ alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexaoxy).

In one embodiment, R^4 represents hydrogen or $\text{C}_1\text{-C}_4$ alkyl optionally substituted with one or two substituents independently selected from hydroxyl and $\text{C}_1\text{-C}_4$ alkoxy.

In another embodiment, R^4 represents hydrogen.

In one embodiment of the invention, X represents a single bond or a group -C₁-C₆ alkylene-Y-, wherein Y represents a single bond, oxygen atom, NR²⁴ or S(O)_w; said alkylene being optionally further substituted by OH, halogen, CN, NR³⁷R³⁸, C₁-C₃ alkoxy, CONR³⁹R⁴⁰, CO₂R⁶⁶, SO₂R⁴¹ and SO₂NR⁴²R⁴³.

In one embodiment of the invention, X represents a single bond or a group -C₁-C₆ alkylene-Y-, wherein Y represents a single bond, oxygen atom, NR²⁴ or S(O)_w; said alkylene being optionally further substituted by OH, halogen, CN, NR³⁷R³⁸, C₁-C₃ alkoxy, CONR³⁹R⁴⁰, CO₂R⁶⁶, SO₂R⁴¹ and SO₂NR⁴²R⁴³.

In an embodiment of the invention, X represents a group -C₁-C₆ alkylene-Y- and Y represents a single bond and the alkylene moiety is a linear or branched C₁-C₆ or C₁-C₄ or C₁-C₂ alkylene, optionally substituted by OH, halogen, CN, CO₂R⁶⁶ or C₁-C₃ alkoxy.

In another embodiment of the invention, X represents unsubstituted C₁-C₂ alkylene, particularly methylene.

20 In another embodiment of the invention, X represents a single bond.

In one embodiment of the invention, R⁴ and X are joined together such that the group -NR⁴X together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR⁴⁴; said ring being optionally substituted by C₁-C₆ alkyl or NR⁴⁵R⁴⁶; said alkyl being optionally further substituted by OH.

Examples of a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR⁴⁴ include pyrrolidine, piperidine, piperazine, morpholine and perhydroazepine.

5 R⁵ represents a monocyclic ring system selected from

- i) phenoxy,
- ii) phenyl,
- iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms) independently selected from nitrogen, 10 oxygen and sulphur,
- iv) a saturated or partially unsaturated C₃-C₆ cycloalkyl ring, or
- v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms) independently selected from oxygen, S(O)_r and NR²⁰, wherein at least one of the ring carbon atoms 15 may be optionally replaced by a carbonyl group,

15 R⁵ represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)_t or C₁-C₆ alkylene optionally 20 comprising one or more (e.g. one or two) internal or terminal heteroatoms selected from oxygen, sulphur and NR²⁷ and being optionally substituted by at least one substituent (e.g. one or two substituents) independently selected from hydroxyl, oxo and C₁-C₆ alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy);

25 the monocyclic or bicyclic ring system being optionally substituted (on a ring atom) by at least one substituent (e.g. one, two or three substituents) independently selected from oxygen (e.g. to form an N-oxide), CN, OH, C₁-C₆ alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C₁-C₆ alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy),

halogen (e.g. fluorine, chlorine, bromine or iodine), $NR^{47}R^{48}$, NO_2 , OSO_2R^{49} , CO_2R^{50} , $C(=NH)NH_2$, $C(O)NR^{51}R^{52}$, $C(S)NR^{53}R^{54}$, $SC(=NH)NH_2$, $NR^{55}C(=NH)NH_2$, $-S(O)_vR^{21}$, $SO_2NR^{56}R^{57}$, $C_1\text{-}C_3$ alkoxy substituted by one or more F atoms (e.g. OCH_2F , $OCHF_2$, OCF_3 , OCH_2CH_2F , OCH_2CF_3 , OCF_2CF_3 , $OCH(CF_3)_2$ and $OCH_2CH_2CF_3$) and $C_1\text{-}C_3$ alkyl substituted by SO_2R^{58} or by one or more F atoms (e.g. $CH_2SO_2R^{58}$, $CH_2CH_2SO_2R^{58}$, $CH(SO_2R^{58})CH_3$, CH_2F , CHF_2 , CF_3 , CH_2CH_2F , CH_2CF_3 , CF_2CF_3 , $CH(CF_3)_2$ and $CH_2CH_2CF_3$); said $C_1\text{-}C_6$ alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, $C_1\text{-}C_6$ alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexaoxy), $C_1\text{-}C_6$ alkylthio (e.g. methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio, n-pentylthio or n-hexylthio) and $-C(O)NR^{22}R^{23}$;

or R^5 may also represent hydrogen.

Examples of a 5- or 6-membered heteroaromatic ring include furanyl, thienyl, pyrrolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyrimidinyl and pyrazinyl. Preferred heteroaromatic rings include isoxazolyl, pyridinyl, imidazolyl and triazolyl.

Unless otherwise indicated, a “saturated or partially unsaturated $C_3\text{-}C_6$ cycloalkyl ring” denotes a 3- to 6-membered non-aromatic cycloalkyl ring optionally incorporating one or more double bonds, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl. A preferred cycloalkyl ring is cyclopropyl.

Unless otherwise indicated, a “saturated or partially unsaturated 4- to 7-membered heterocyclic ring” as specified above denotes a 4- to 7-membered non-aromatic heterocyclic ring optionally incorporating one or more double bonds and optionally incorporating a carbonyl group, examples of which include tetrahydrofuran, tetramethylenesulfonyl, tetrahydropyran, 4-oxo-4H-pyran-4-onyl),

pyrrolidinyl, 3-pyrrolinyl, imidazolidinyl, 1,3-dioxolanyl (1,3-dioxacyclopentanyl), piperidinyl, piperazinyl, morpholinyl, perhydroazepinyl (hexamethylene iminyl), pyrrolidonyl and piperidonyl. A preferred saturated or partially unsaturated 4- to 7-membered heterocyclic ring is pyrrolidonyl.

5

Examples of bicyclic ring systems in which the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group include biphenyl, thienylphenyl, pyrazolylphenyl, phenoxyphenyl, phenylcyclopropyl, naphthyl, indanyl, quinolyl, tetrahydroquinolyl, benzofuranyl, indolyl, isoindolyl, 10 indoliny, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, isoquinolyl, chromanyl, indenyl, quinazolyl, quinoxalyl, chromanyl, isocromanyl, 3H-indolyl, 1H-indazolyl, quinuclidyl, tetrahydronaphthyl, dihydrobenzofuranyl, morpholine-4-ylphenyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxinyl and 3,4-dihydro-isochromenyl.

15

In an embodiment of the invention, R^5 represents a substituted monocyclic ring system as defined above.

20

In another embodiment of the invention, R^5 represents a substituted bicyclic ring system as defined above.

In another embodiment of the invention, R^5 represents H. In another embodiment of the invention, X represents a single bond and R^5 represents H.

25

In a further embodiment of the invention, R^5 represents a monocyclic ring system selected from

- phenoxy,
- phenyl,
- a 5- or 6-membered heteroaromatic ring comprising one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur,

30

- iv) a saturated or partially unsaturated C₃-C₆ cycloalkyl ring, or
- v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising one or two ring heteroatoms independently selected from oxygen, S(O)_r and NR²⁰,
5 wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group;
or R⁵ represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, methylene and S(O)_t;
- 10 the monocyclic or bicyclic ring system being substituted by one or two substituents independently selected from OH, -S(O)_vR²¹ and C₁-C₄ alkyl.

In a still further embodiment of the invention, R⁵ represents a monocyclic ring system selected from phenyl or a 5- or 6-membered heteroaromatic ring comprising one or two 15 ring heteroatoms independently selected from nitrogen and oxygen, the monocyclic ring system being substituted by one or two substituents independently selected from OH, -S(O)_vR²¹ and C₁-C₄ alkyl.

In a still further embodiment of the invention, R⁵ represents phenyl or pyridinyl substituted 20 by -S(O)_vR²¹ wherein v represents the integer 2.

In a still further embodiment of the invention, R⁵ represents phenyl substituted by one or 25 two substituents independently selected from OH, -S(O)_vR²¹ and C₁-C₄ alkyl.

In a still further embodiment of the invention, R⁵ represents an unsubstituted C₃-C₆ cycloalkyl ring, particularly cyclopropyl.

In one embodiment, x is 2.

In one embodiment, p is 2.

In one embodiment, R¹⁰ and R¹¹ independently represent H, C₁-C₃ alkyl or

5 C₂-C₃ alkylcarbonyl.

In one embodiment, R¹² and R¹³ independently represent H, C₁-C₃ alkyl or

C₂-C₃ alkylcarbonyl.

10 In a further embodiment, R²⁰ represents hydrogen, methyl, ethyl, methylcarbonyl (acetyl), ethylcarbonyl, methoxycarbonyl or ethoxycarbonyl.

In one embodiment, v is 2.

15 R²¹ represents hydrogen, C₁-C₆ alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C₃-C₈ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl); said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, C₁-C₃ alkoxy and CONR⁵⁹R⁶⁰.

20

In an embodiment according to the invention, R²¹ represents C₁-C₄ alkyl or C₃-C₆ cycloalkyl.

25 In another embodiment, R²¹ represents C₁-C₃ alkyl (particularly methyl, ethyl or isopropyl) or cyclopropyl.

In another embodiment, R⁴¹ represents C₁-C₃ alkyl (particularly methyl, ethyl or isopropyl) or cyclopropyl.

In an embodiment of the invention, R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{30} , R^{33} , R^{34} , R^{35} , R^{36} , R^{37} , R^{38} , R^{47} , R^{48} , R^{61} , R^{22} , R^{23} , R^{24} , R^{26} , R^{27} , R^{31} , R^{32} , R^{39} , R^{40} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} , R^{49} , R^{50} , R^{51} , R^{52} , R^{53} , R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{60} , R^{62} , R^{63} , R^{64} , R^{65} and R^{66}

5 each independently represent hydrogen or C₁-C₃ alkyl, particularly methyl, ethyl, 1-propyl or 2-propyl.

In an embodiment of the invention, R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{30} , R^{33} , R^{34} , R^{35} , R^{36} , R^{37} , R^{38} , R^{47} , R^{48} , R^{61} , R^{22} , R^{23} , R^{24} , R^{26} , R^{27} , R^{31} , R^{32} , R^{39} , R^{40} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} , R^{49} , R^{50} , R^{51} , R^{52} , R^{53} , R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{60} , R^{62} , R^{63} , R^{64} , R^{65} and R^{66}

10 each independently represent hydrogen or methyl.

In an embodiment of the invention, R^{66} represents hydrogen.

15 In an embodiment of the invention,

R^1 represents methyl;

W represents a phenyl ring, and the group R^{14} and the 2-pyrazinone ring are bonded to the phenyl ring W in a 1,2-relationship;

20 R^{14} represents phenyl or pyridinyl; said ring being optionally substituted in the 4-(para) position with F, Cl, CN or CF₃;

R^3 represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;

R^4 represents hydrogen;

X represents unsubstituted C₁-C₂ alkylene, particularly methylene; and

25 R^5 represents phenyl substituted by one or two substituents independently selected from OH, -S(O)_vR²¹ and C₁-C₄ alkyl wherein v represents the integer 2.

In an embodiment of the invention,

R^1 represents methyl;

W represents a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms, and the group R^{14} and the 2-pyrazinone ring are bonded to the heteroaromatic ring 5 W in a 1,2-relationship;

R^{14} represents phenyl or pyridinyl; said ring being optionally substituted in the 4-(para) position with F, Cl, CN or CF_3 ;

10 R^3 represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;

R^4 represents hydrogen;

X represents unsubstituted C_1 - C_2 alkylene, particularly methylene; and

15 R^5 represents phenyl substituted by one or two substituents independently selected from OH , $-S(O)_vR^{21}$ and C_1 - C_4 alkyl wherein v represents the integer 2.

15

In an embodiment of the invention,

R^1 represents methyl;

20 W represents a phenyl ring, and the group R^{14} and the 2-pyrazinone ring are bonded to the phenyl ring W in a 1,2-relationship;

R^{14} represents phenyl or pyridinyl; said ring being optionally substituted in the 4-(para) position with F, Cl, CN or CF_3 ;

25 R^3 represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;

R^4 represents hydrogen;

X represents a single bond or unsubstituted C_1 - C_2 alkylene, particularly methylene; and

R^5 represents H.

In an embodiment of the invention,

R^1 represents methyl;

5 W represents a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms, and the group R^{14} and the 2-pyrazinone ring are bonded to the heteroaromatic ring W in a 1,2-relationship;

R^{14} represents phenyl or pyridinyl; said ring being 4- (para) substituted with F, Cl or CN;

10 R^3 represents a phenyl group substituted in the meta position with Br, Cl, CF_3 or CN;

R^4 represents hydrogen;

X represents a single bond or unsubstituted C_1 - C_2 alkylene, particularly methylene; and

R^5 represents H.

15

Examples of compounds of the invention include:

N -([6-(4'-cyanobiphenyl-2-yl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazin-2-yl]carbonyl)glycine;

3'-(4-cyanophenyl)-3-methyl-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-2,2'-

20 bipyrazine-6-carboxamide;

6-[4-(4-cyanophenyl)pyrimidin-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide;

6-[2-(4-cyanophenyl)pyridin-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide;


25 and pharmaceutically acceptable salts of any one thereof.

Compound names were generated using the software ACD Labs version 6.00.

Corresponding molecular structures are shown in the Examples section.

The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises,


5 (a) reacting a compound of formula (II)



(II)

wherein L¹ represents a leaving group (such as halogen or hydroxyl) and R¹, R³, R¹⁴ and W are as defined in formula (I),


10 with a compound of formula



wherein X, R⁴ and R⁵ are as defined in formula (I); or

(b) reacting a compound of formula (IV)

15




(IV)

wherein Hal represents a halogen atom and X, R¹, R³, R⁴ and R⁵ are as defined in formula (I),

with a nucleophile $R^{14}-W-M$ wherein R^{14} and W are as defined in formula (I) and M represents an organo-tin or organo boronic acid group; or

(c) reacting a compound of formula (V)

5



(V)

wherein Hal represents a halogen atom and W, X, R¹, R³, R⁴ and R⁵ are as defined in formula (I),

with a nucleophile $R^{14}-M$ wherein R^{14} is as defined in formula (I) and M represents an

10 organo-tin or organo boronic acid group;

and optionally after (a), (b) or (c) carrying out one or more of the following:

- converting the compound obtained to a further compound of the invention
- forming a pharmaceutically acceptable salt of the compound.

15 In process (a), the reaction may conveniently be carried out in an organic solvent such as dichloromethane or N-methylpyrrolidinone at a temperature, for example, in the range from 0 °C to the boiling point of the solvent. If necessary or desired, a base and/or a coupling reagent such as HATU (O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate), HOAT (1-Hydroxy-7-azabenzotriazole),
20 HOBT (1-Hydroxybenzotriazole hydrate) or DIEA (N,N-Diisopropylethylamine) may be added.

In processes (b) and (c), the reaction may conveniently be carried out in an organic solvent such as DMF, NMP or toluene or a mixture thereof at elevated temperature (i.e. above
25 ambient temperature, 20°C), for example, in the range from 50 °C to 150 °C and in the

presence of a suitable transition metal catalyst such as bis(*tri-t*-butylphosphine)palladium. If necessary or desired, a base such as potassium carbonate may be added.

Specific processes for the preparation of compounds of Formula (I) are disclosed within the Examples section of the present specification. Such processes form an aspect of the present invention.

The necessary starting materials are either commercially available, are known in the literature or may be prepared using known techniques. Specific processes for the preparation of certain key starting materials are disclosed within the Examples section of the present specification and such processes form an aspect of the present invention.

Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures.

Certain intermediates of formulae (II), (IV) and (V) are novel. Such novel intermediates form another aspect of the invention.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the addition and/or removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide,

sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate or *p*-toluenesulphonate.

Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers (including atropisomers) of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired.

10 The compounds of formula (I) and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as modulators of serine proteases such as proteinase 3 and pancreatic elastase and, especially, human neutrophil elastase, and may therefore be beneficial in the treatment or prophylaxis of inflammatory diseases and conditions.

15 The compounds of formula (I) and their pharmaceutically acceptable salts can be used in the treatment of diseases of the respiratory tract such as obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-

20 responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis

25 including rhinitis nervosa (hay fever); nasal polypsis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus.

The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of bone and joints such as arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection-related arthropathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthalgias, tendonititides, and myopathies.

The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of pain and connective tissue remodelling of musculoskeletal disorders due to injury [for example, sports injury] or disease: arthritides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritis, scleroderma, mixed connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis).

The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of skin such as psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, 5 pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other 10 dysplastic lesions; drug-induced disorders including fixed drug eruptions.

The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the eye such as blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; 15 autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial.

The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in 20 the treatment of diseases of the gastrointestinal tract such as glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, non-inflammatory diarrhoea, and food-related allergies which may have effects remote from the gut (for example, migraine, rhinitis or eczema).

25 The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the cardiovascular system such as atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis, inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; 30 endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.

The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in oncology such as in the treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies
5 affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes.

In particular, the compounds of formula (I) and their pharmaceutically acceptable salts may
10 be used in the treatment of adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer,
15 atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis and gastric mucosal injury.

More particularly, the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, asthma and rhinitis.

20 Even more particularly, the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of chronic obstructive pulmonary disease (COPD).

Thus, the present invention provides a compound of formula (I) or a pharmaceutically-
25 acceptable salt thereof as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.

30 In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a

medicament for the treatment of human diseases or conditions in which modulation of neutrophil elastase activity is beneficial.

In a further aspect, the present invention provides the use of a compound of formula (I) or
5 a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in the treatment of an inflammatory disease or condition.

In a further aspect, the present invention provides the use of a compound of formula (I) or
a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a
10 medicament for use in treating adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, 15 atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis and gastric mucosal injury.

In a further aspect, the present invention provides the use of a compound of formula (I) or
a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a
medicament for use in treating chronic obstructive pulmonary disease (COPD).

20 In a further aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined for the treatment of human diseases or conditions in which modulation of neutrophil elastase activity is beneficial.

25 In a further aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined for the treatment of an inflammatory disease or condition.

30 In a further aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined for the treatment of adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis

including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers,
5 Crohn's disease, ulcerative colitis and gastric mucosal injury.

In a further aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined for the treatment of chronic obstructive pulmonary disease (COPD).

10

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

15

Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly
20 susceptible to developing the disease or condition.

25

The invention also provides a method of treating, or reducing the risk of, a disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

30

The invention still further provides a method of treating, or reducing the risk of, an inflammatory disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

The invention still further provides a method of treating, or reducing the risk of, adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, 5 ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis and gastric mucosal injury which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

10

The invention still further provides a method of treating, or reducing the risk of, chronic obstructive pulmonary disease (COPD) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

15

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of the invention may be in the range from 0.05 mg/kg to 100 mg/kg.

20

The compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Conventional procedures 25 for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

30

Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.

10

The pharmaceutical compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler®; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.

15

Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation. For inhalation, the compound is desirably finely divided. The finely divided compound preferably has a mass median diameter of less than 10 µm, and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C₈-C₂₀ fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.

20

The compounds of the invention may also be administered by means of a dry powder inhaler. The inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.

25

One possibility is to mix the finely divided compound of the invention with a carrier substance, for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol.

Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. Alternatively the finely divided compound may be coated by another substance. The powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active
5 compound.

Another possibility is to process the finely divided powder into spheres which break up during the inhalation procedure. This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler® in which a
10 dosing unit meters the desired dose which is then inhaled by the patient. With this system the active ingredient, with or without a carrier substance, is delivered to the patient.

For oral administration the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato
15 starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be
20 coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.

For the preparation of soft gelatine capsules, the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules
25 may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.

Liquid preparations for oral application may be in the form of syrups or suspensions, for
30 example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or

carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.

The compounds of the invention may also be administered in conjunction with other

5 compounds used for the treatment of the above conditions.

Thus, the invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or 10 sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.

In particular, for the treatment of the inflammatory diseases such as (but not restricted to) rheumatoid arthritis, osteoarthritis, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), psoriasis, and inflammatory bowel disease, the compounds of the

15 invention may be combined with agents listed below.

Non-steroidal anti-inflammatory agents (hereinafter NSAIDs) including non-selective cyclo-oxygenase COX-1 / COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, 20 azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); selective COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); cyclo-oxygenase inhibiting nitric oxide donors (CINODs); glucocorticosteroids (whether administered by topical, oral, intramuscular, intravenous, or intra-articular routes); methotrexate; leflunomide; hydroxychloroquine; d-penicillamine; 25 auranofin or other parenteral or oral gold preparations; analgesics; diacerein; intra-articular therapies such as hyaluronic acid derivatives; and nutritional supplements such as glucosamine.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a cytokine or agonist 30 or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma-interferons; insulin-like growth factor type I (IGF-1); interleukins (IL) including IL1 to 23,

and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha (TNF- α) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxyfylline.

5 In addition the invention relates to a combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a monoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax II-15).

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a modulator of chemokine receptor function such as an antagonist of CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

10 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an inhibitor of matrix metalloprotease (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP-12, including agents such as doxycycline.

15 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2-alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.

20 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a receptor antagonist for leukotrienes (LT) B4, LTC4, LTD4, and LTE4. selected from the group consisting of the phenothiazin-3-1s

such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

5 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.

10 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.

15 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a proton pump inhibitor (such as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an antagonist of the histamine type 4 receptor.

20 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an alpha-1/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.

25 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an anticholinergic agents including muscarinic receptor (M1, M2, and M3) antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pирbutерол, or a chiral 5 enantiomer thereof.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a chromone, such as sodium cromoglycate or nedocromil sodium.

The present invention still further relates to the combination of a compound of the 10 invention, or a pharmaceutically acceptable salt thereof, with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an agent that modulates a nuclear hormone 15 receptor such as PPARs.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and another systemic or topically-applied anti- 20 inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.

The present invention still further relates to the combination of a compound of the 25 invention, or a pharmaceutically acceptable salt thereof, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.

The present invention further relates to the combination of a compound of the invention, or 30 a pharmaceutically acceptable salt thereof, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir,

famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcriptase inhibitor such as nevirapine or efavirenz.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxyfylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegiline and rasagiline, a comP inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of neuronal nitric oxide synthase), or an anti-Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitriptyline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.

A compound of the present invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an anti-osteoporosis agent including a hormonal agent such as raloxifene, or a biphosphonate such as alendronate.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a: (i) tryptase

inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of a MAP kinase such as p38, JNK, protein kinase A, B or C, or IKK), or a kinase involved in cell cycle regulation (such as a cyclin dependent kinase); (viii) glucose-6 phosphate dehydrogenase inhibitor; (ix) kinin-B₁ or B₂-receptor antagonist; (x) anti-gout agent, for example colchicine; (xi) xanthine oxidase inhibitor, for example allopurinol; (xii) uricosuric agent, for example probenecid, sulfinpyrazone or benzboromarone; (xiii) growth hormone secretagogue; (xiv) transforming growth factor (TGF β); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor for example basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykinin NK₁ or NK₃ receptor antagonist such as NKP-608C, SB-233412 (talnetant) or D-4418; (xx) elastase inhibitor such as UT-77 or ZD-0892; (xxi) TNF-alpha converting enzyme inhibitor (TACE); (xxii) induced nitric oxide synthase (iNOS) inhibitor; (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, (such as a CRTH2 antagonist); (xxiv) inhibitor of P38; (xxv) agent modulating the function of Toll-like receptors (TLR), (xxvi) agent modulating the activity of purinergic receptors such as P2X7; or (xxvii) inhibitor of transcription factor activation such as NFkB, API, or STATS.

A compound of the invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an existing therapeutic agent for the treatment of cancer, for example suitable agents include:

(i) an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a

topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin);

(ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leupreorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5 α -reductase such as finasteride;

10 (iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function);

(iv) an inhibitor of growth factor function, for example: a growth factor antibody (for example the anti-erbB2 antibody trastuzumab, or the anti-erbB1 antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), an

15 inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family;

(v) an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or

20 WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin α v β 3 function or an angiostatin);

(vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213;

(vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense;

(viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme

pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or
5 (ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

10

In particular the compounds of the invention may be administered in conjunction with a second active ingredient which is selected from:

- a) a PDE4 inhibitor including an inhibitor of the isoform PDE4D;
- b) a β -adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, 15 albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol or indacaterol;
- c) a muscarinic receptor antagonist (for example a M1, M2 or M3 antagonist, such as a selective M3 antagonist) such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
- d) a modulator of chemokine receptor function (such as a CCR1 or CCR8 receptor 20 antagonist);
- e) an inhibitor of kinase function;
- f) a non-steroidal glucocorticoid receptor agonist;
- g) a steroidal glucocorticoid receptor agonist; and
- 25 h) a protease inhibitor (such as a MMP12 or MMP9 inhibitor);

The present invention will now be further explained by reference to the following illustrative examples.

30

General Methods

^1H NMR and ^{13}C NMR spectra were recorded on a Varian *Inova* 400 MHz or a Varian *Mercury-VX* 300 MHz instrument. The central peaks of chloroform-*d* (δ_{H} 7.27 ppm),

dimethylsulfoxide-*d*₆ (δ_H 2.50 ppm), acetonitrile-*d*₃ (δ_H 1.95 ppm) or methanol-*d*₄ (δ_H 3.31 ppm) were used as internal references. Column chromatography was carried out using silica gel (0.040-0.063 mm, Merck). Unless stated otherwise, starting materials were commercially available. All solvents and commercial reagents were of laboratory grade
5 and were used as received.

The following method was used for LC/MS analysis:

Instrument Agilent 1100; Column Waters Symmetry 2.1 x 30 mm; Mass APCI; Flow rate 0.7 ml/min; Wavelength 254 nm; Solvent A: water + 0.1% TFA; Solvent B: acetonitrile +
10 0.1% TFA ; Gradient 15-95%/B 8 min, 95% B 1 min.


Analytical chromatography was run on a Symmetry C₁₈-column, 2.1 x 30 mm with 3.5 μ m particle size, with acetonitrile/water/0.1% trifluoroacetic acid as mobile phase in a gradient from 5% to 95% acetonitrile over 8 minutes at a flow of 0.7 ml/min.

15


The abbreviations or terms used in the examples have the following meanings:

THF: Tetrahydrofuran
TFA: Trifluoroacetic acid
DCM: Dichloromethane
20 DMF: N,N-Dimethylformamide
EtOAc: Ethyl acetate
DMSO: Dimethyl sulphoxide
NMP: N-Methylpyrrolidinone
SM: Starting material
25 RT: Room temperature

Example 1



N-((6-(4'-Cyanobiphenyl-2-yl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazin-2-yl)carbonyl)glycine



Reagents: a). (2-chlorophenyl)boronic acid, $\text{Pd}(\text{PPh}_3)_4$, aq. Na_2CO_3 , tol, b). *tert*-butyl glycinate hydrochloride, 1,1'-carbonyl diimidazole, DMF, c). (4-cyanophenyl) boronic acid, $\text{Pd}(\text{PPh}_3)_4$, aq. Na_2CO_3 , tol.

5

Aqueous Na_2CO_3 (6 ml, 2M) was added to a mixture of SM2 (1.6 g, 4.09 mmol) and (2-chlorophenyl)boronic acid (1.28 g, 8.18 mmol) in toluene (10 mL). This mixture was degassed by flushing with N_2 gas. $\text{Pd}(\text{PPh}_3)_4$ (0.2 g) was added and the reaction mixture was stirred at 105 °C for 3h, cooled to RT, and partitioned between ethyl acetate (400 ml) and water (100 ml). The aqueous phase was concentrated and the residue was purified by HPLC (20-90% acetonitrile in water containing 0.1% TFA) to give 6-(2-chlorophenyl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylic acid (0.58 g, 38%).

10

15 ^1H NMR (400 MHz, DMSO-d_6) δ 8.05 (br.s, 1H); 7.99-7.80 (m, 3H); 7.61 (m, 1H); 7.50 (m, 3H); 1.78 (s, 3H).

APCI-MS m/z : 409.0 $[\text{MH}^+]$.

A mixture of 6-(2-chlorophenyl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylic acid (0.409 g, 1 mmol) and 1,1-carbonyl diimidazole (0.243 g, 1.5 mmol) in DMF (5 ml) was stirred at RT for 50 min. To this solution was added *tert*-

20

butyl glycinate hydrochloride (0.335 g, 2 mmol) followed by Et₃N (0.416 ml, 3 mmol) and after 2h at RT the reaction mixture was partitioned between ethyl acetate (300 ml) and water (50 ml). The organic layer was dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel flash chromatography (0-2%
5 methanol in DCM) to give *tert*-butyl *N*-(6-(2-chlorophenyl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazin-2-yl carbonyl)glycinate (0.45 g, 86%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.44 (t, *J* = 5.1 Hz, 1H); 8.05 (m, 1H); 7.96 (d, *J* = 7.2 Hz, 1H); 7.91-7.82 (m, 2H); 7.66-7.62 (m, 1H); 7.53-7.49 (m, 3H); 3.97 (d, *J* = 5.8 Hz, 2H); 1.83 (s, 3H); 1.42 (s, 9H).


10 APCI-MS ^{m/z}: 522.0 [MH⁺].

To a mixture of *tert*-butyl *N*-(6-(2-chlorophenyl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazin-2-yl carbonyl)glycinate (0.1 g, 0.19 mmol) and (4-cyanophenyl)boronic acid (0.147 g, 1 mmol) in toluene (2 ml) was added aqueous
15 Na₂CO₃ (212 mg Na₂CO₃ in 1 ml water). This mixture was degassed by flushing with N₂ gas. To this reaction mixture was added Pd(PPh₃)₄ (0.1 g, 0.09 mmol) and the mixture was stirred at 105 °C for 7h then at 130 °C for 6h. The reaction mixture was cooled to RT, and partitioned between ethyl acetate (150 ml) and water (50 ml). The organic layer was dried over Na₂SO₄, filtered and the filtrate was concentrated in vacuo. The residue was dissolved
20 in DCM (4.5 ml), TFA (1.5 ml) was added and after 3.5 h at RT, the volatiles were removed in vacuo. The residue was purified by HPLC (10-80% acetonitrile in water containing 0.1% TFA) to give *N*-(6-(4'-cyanobiphenyl-2-yl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazin-2-yl carbonyl)glycine (3 mg).

¹H NMR (400 MHz, CD₃OD) δ 7.90-7.40 (m, 12H), 4.18 (s, 2H); 1.58 (s, 3H).

25 APCI-MS ^{m/z}: 533.0 [MH⁺].

Example 2



3'-(4-Cyanophenyl)-3-methyl-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-2,2'-bipyrazine-6-carboxamide

In a three-necked flask 2,3-dichloropyrazine (1.52 g, 10.2 mmol), toluene (48 mL), tri-*o*-tolylphosphine (0.041 g, 0.14 mmol), palladium(II)acetate (0.015 g, 0.070 mmol) and 2M sodium carbonate (21 mL, 42 mmol) were mixed. The flask was evacuated and backfilled with argon three times. After stirring for 10 minutes, a solution of 4-cyanophenylboronic acid (1.0 g, 6.8 mmoles) and absolute ethanol (18 mL) was added. The mixture was stirred rapidly at 73 °C for 1h and at ambient temperature overnight. Water (30 mL) was added to the clear yellow solution which was then washed with ethyl acetate (2 x 50 mL). The organic phases were combined, washed with brine (1 x 30 mL), dried over anhydrous sodium sulfate, filtered and concentrated with silica to dryness. Flash chromatography on silica with ethyl acetate/n-heptane (1:20 and 1:8) as eluents gave 4-(3-chloropyrazin-2-yl)benzonitrile (0.59 g, 40% yield) as a white solid.

¹⁵ ¹H NMR (CDCl₃): δ 8.65 (d, *J* = 2.6 Hz, 1H), 8.44 (d, *J* = 2.3 Hz, 1H), 7.96 (d, *J* = 8.4 Hz, 2H), 7.81 (d, *J* = 8.4 Hz, 2H) ppm.

FT-IR (film) ν 2227.3 (str), 1369.7 (v str), 842.3 (v str) cm⁻¹.

APCI-MS *m/z* 215.7 [M⁺].

²⁰ 4-(3-Chloropyrazin-2-yl)benzonitrile (0.66 g), phosphorous tribromide (5.0 mL) and xylenes (35 mL) were refluxed in a flask with CaCl₂-tube for 3h. The reaction was left overnight at RT. The light yellow solution was poured onto crushed ice in a beaker with a stirring magnet and the mixture stirred until the ice melted. The phases were separated and the aqueous phase was washed with ethyl acetate (2 x 100 mL). The combined organic phases were washed with brine (100 mL), made alkaline with saturated sodium carbonate (pH>9), dried over anhydrous sodium sulfate, filtered and concentrated to give a white semi-solid product. This material was dissolved in DCM (70 mL), concentrated with silica

to dryness and applied to a silica column. Flash chromatography with ethyl acetate/n-heptane (1:8 through 1:4) as eluents gave 4-(3-bromopyrazin-2-yl)benzonitrile (0.72 g, 94%) as a white solid.

¹H NMR (CDCl₃): δ 8.65 (d, *J* = 2.5 Hz, 1H), 8.41 (d, *J* = 2.5 Hz, 1H), 7.91 (d, *J* = 8.4 Hz,

5 2H), 7.81 (d, *J* = 8.4 Hz, 2H) ppm.

APCI-MS *m/z* 260/262 [MH⁺].

In a dry flask, dry acetonitrile (2.4 ml), cobalt (II)bromide (16 mg, 0.075 mmol), anhydrous zinc bromide (19 mg, 0.080 mmol), bromobenzene (7.9 μ L, 0.075 mmol) and 10 zinc dust (163 mg, 2.5 mmol) were placed under argon. TFA (0.0030 mL, 0.030 mmol) was added and the mixture was stirred at RT for 20 minutes. Methyl 6-bromo-5-methyl-3-oxo-4-(3-(trifluoromethyl)phenyl)-3,4-dihydropyrazine-2-carboxylate (SM2, 147 mg, 0.38 mmol) was added to the solution and the reaction mixture was stirred at RT. After 4h, the solids were allowed to settle. The dark supernatant was withdrawn with a syringe and 15 transferred to a dry flask furnished with a magnetic stirrer, septum and argon inlet. 4-(3-Bromopyrazin-2-yl)benzonitrile (101 mg, 0.39 mmol), bis(tri-tert-butylphosphine)palladium(0) (10.2 mg, 0.020 mmol) and dry MeCN (1.4 mL) were added. The mixture was stirred under argon at 45 °C for 4h. The dark red solution was concentrated, taken up in EtOAc and washed with brine. The organic phase was dried over 20 anhydrous sodium sulfate, filtered and concentrated with silica to dryness. Flash chromatography on silica with ethyl acetate /n-heptane (1:4 through 2:1) as eluents gave unreacted 4-(3-bromopyrazin-2-yl)benzonitrile (0.090 g). Elution with neat ethyl acetate gave methyl 3'-(4-cyanophenyl)-3-methyl-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-2,2'-bipyrazine-6-carboxylate (0.017 g, 9%) as a dark yellow oil. (cf. Fillon *et al.* 25 J. Amer. Chem. Soc. 2003, 125, 3867-3870)

¹H NMR (CD₂Cl₂): δ 8.74 (d, *J* = 2.6 Hz, 1H), 8.69 (d, *J* = 2.6 Hz, 1H), 7.83 (d, *J* = 8.8 Hz, 1H), 7.76 (partially obscured t, *J* = 8.8 Hz, 1H), 7.73 (d, *J* = 8.8 Hz, 2H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.45 (br s, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 3.81 (s, 3H), 1.87 (s, 3H) ppm. APCI-MS *m/z* 491.9 [MH⁺].


Methyl 3'-(4-cyanophenyl)-3-methyl-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-2,2'-bipyrazine-6-carboxylate (0.016 g, 0.03 mmol) and 7.0M ammonia in methanol (1 mL, 7.00 mmol) were mixed in a vial and run in a Biotage microwave reactor at 60 °C for 7 minutes. The solution was concentrated in a stream of dry nitrogen. Purification by 5 reversed-phase HPLC with acetonitrile-water (60 through 95%) as eluent (no buffer or acid added) gave 3'-(4-cyanophenyl)-3-methyl-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-2,2'-bipyrazine-6-carboxamide (0.0050 g) as a light pink solid after concentration. HPLC-purity: 98-99%.

¹H NMR (CD₃CN): δ 8.77 (d, J = 2.4 Hz, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.29 (br s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.81 (partially obscured t, J = 8.0 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.62 (br s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 6.25 (br s, 1H), 1.82 (s, 3H) ppm.

10 APCI-MS m/z 476.9 [M⁺].

15

Example 3



6-[4-(4-Cyanophenyl)pyrimidin-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide

20 iPrMgCl-LiCl (23.5 ml, 23.8 mmol, 14% in THF) was added to a dried argon flushed container and was cooled in an ethanol/CO₂-bath in order to get an internal temperature of around -15 °C. 4-Iodobenzonitrile (5.2 g, 22.7 mmol) was added in one portion and the mixture was stirred for 30 min at -10 °C. 5-Bromopyrimidin (4 g, 25 mmol) was added and the mixture was stirred at 0 °C for 60 min. Product was formed and no starting material was left according to LC-MS. The mixture was quenched with an aqueous solution of NH₄Cl and extracted with EtOAc. The organic phase was concentrated. The crude yellow oil was dissolved in acetone (300 ml) and KMnO₄ in acetone (400 ml) was

25

added until the mixture stayed red. The mixture was filtered and half of the solvent was evaporated off. Water was added and the mixture was extracted with EtOAc. The organic phase was then extracted with a solution of 0.3M HCl, dried with MgSO₄ and evaporated to give 4-(5-bromopyrimidin-4-yl)benzonitrile (2.67 g, 45 %).

5 APCI-MS ^{m/z}: 260, 262 [MH⁺].

4-(5-Bromopyrimidin-4-yl)benzonitrile (362 mg, 1.39 mmol), potassium acetate (410 mg, 4.1 mmol), PdCl₂(dppf) (34 mg, 0.042 mmol) and bis(pinacolato)diboron (388 mg, 1.53 mmol) were mixed in dioxane (4 ml) and flushed with argon. The mixture was stirred 10 overnight at 100 °C. EtOAc was added and the mixture was extracted with a solution of 0.5M NaOH. The aqueous phase was washed with EtOAc and the pH was adjusted to 6 with a solution of HCl in water. It was then extracted with EtOAc. The organic phase was washed with brine, dried with MgSO₄ and evaporated to give 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-4-yl]benzonitrile (189 mg, 44%).

15 ¹H NMR (399.99 MHz, DMSO-*d*₆) δ 9.35 (s, 1H), 9.00 (s, 1H); 7.98 (d, 2H), 7.85 (d, 2H), 1.24 (s, 12H).

APCI-MS ^{m/z}: 226 [MH⁺].


Methyl 6-bromo-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxylate (SM2, 63.7 mg, 0.16 mmol) and 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-4-yl]benzonitrile (50 mg, 0.16 mmol) in THF (1 ml) were degassed with argon. Potassium fluoride (47.3 mg, 0.81 mmol) and water (30 µl) were added and the mixture was degassed. Pd₂dba₃ (3.28 mg, 0.0036 mmol) was added and the mixture was degassed again. Tri-tertbutyl phosphine (1.45 mg, 0.0072 mmol) was added and the mixture was degassed three times and then stirred at 45 °C overnight. EtOAc was added and the mixture was washed with a solution of NaHCO₃. The organic phase was evaporated. The crude product was purified by preparative HPLC (water/MeCN/1% TFA) to give methyl 6-[4-(4-cyanophenyl)pyrimidin-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxylate (18 mg, 23 %).

30 APCI-MS ^{m/z}: 492 [MH⁺].

Methyl 6-[4-(4-cyanophenyl)pyrimidin-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxylate (18 mg, 0.04 mmol) and 7M ammonia in methanol (500 μ l) were stirred at 50 °C for 0.5h. The mixture was purified by 5 preparative HPLC (water/MeCN/1% TFA) to obtain 6-[4-(4-cyanophenyl)pyrimidin-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxamide (13 mg, 71%).

¹H NMR (400 MHz, DMSO-*d*₆) δ 9.40 (s, 1H); 9.02 (s, 1H), 8.22 (br s, 1H), 7.93 (d, 3H); 7.85 (t, 1H), 7.81 - 7.75 (m, 3H); 7.66 (br s, 1H); 1.53 (s, 3H).
10 APCI-MS m/z: 477 [MH⁺].

Example 4



¹⁵ 6-[2-(4-Cyanophenyl)pyridin-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxamide

In a microwave sample tube was added SM1 (0.22 g, 0.5 mmol), 2-chloropyridine-3-boronic acid (0.095 g, 0.6 mmol), CH₃CN (3 ml), 2M Na₂CO₃ (1 ml) and Pd(dppf)Cl₂ (10 mg). The solution was degassed with nitrogen and was sealed with a suitable lid. The 20 mixture was heated with stirring in a Biotage microwave synthesis heater to 100 °C for 10 minutes. The mixture was dissolved in EtOAc (20 ml) and was washed with water (20 ml) and brine (10 ml). Evaporation gave an oil, which was purified on silica, to give 6-(2-chloro-pyridin-3-yl)-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid methyl ester (0.12 g, 55%) as a yellowish oil.

²⁵ APCI-MS m/z: 424.3 [MH⁺].

In a microwave sample tube was added 6-(2-chloro-pyridin-3-yl)-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid methyl ester (0.10 g, 0.236 mmol), 4-cyanophenyl-tributylstannane (0.12 g, 0.306 mmol, prepared according to literature procedures), Pd(PBu^t₃)₂ (10 mg) and NMP (3.5 ml). The content of the sample tube was degassed with nitrogen, and sealed with an appropriate lid, and heated in a Biotage synthesis microwave heater at 190 °C for 10 minutes. The mixture was worked up by extraction, and the obtained crude product was purified on silica (heptane:EtOAc 2:1), giving 6-[2-(4-cyano-phenyl)-pyridin-3-yl]-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid methyl ester (85 mg, 73%) as a solid.

APCI-MS m/z: 491.5 [MH⁺].

In a microwave sample tube was dissolved 6-[2-(4-cyano-phenyl)-pyridin-3-yl]-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid methyl ester (0.08 g, 0.16 mmol) in NH₃ (7M in MeOH, 4 ml). The tube was sealed and the mixture was heated at 55 °C for 7 minutes, giving complete formation of the amide according to LC-MS. The volatiles were removed in vacuo, and the residue was purified on preparative HPLC, giving 6-[2-(4-cyanophenyl)pyridin-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide (0.04 g, 52%) as a white solid after freeze-drying the pure fractions.

¹H NMR (300 MHz, DMSO-d₆) δ 8.82 (m, 1H); 8.26 (bs, 1H); 8.03 (d, 1H, *J*=7.9 Hz); 7.94-7.74 (m, 5H); 7.77 (bs, 1H); 7.70 (bs, 1H); 7.66-7.60 (m, 4H); 7.45 (bs, 1H); 1.43 (bs, 1H).

APCI-MS m/z: 476.3 [MH⁺].

25

Starting material SM1

Methyl 6-iodo-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylate

3-Trifluoromethylaniline (5.0 g, 31 mmol) and triethylamine (3.54 g, 35 mmol) were dissolved in DCM (60 ml, dried). The mixture was cooled on ice and to the stirred solution was added dropwise a solution of ethyl oxalyl chloride (4.36 g, 32 mmol) in DCM (15 ml).

After complete addition, the reaction was allowed to stand for 10 minutes. The reaction mixture was washed with water (50 ml), then washed with brine (30 ml), and the organic phase was dried over Na_2SO_4 . Filtration and evaporation gave ethyl oxo{[3-(trifluoromethyl)phenyl]amino}acetate (8.04 g, 99%) as a white solid.

5 ^1H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.19 (s, 1H), 8.03 (d, $J = 8.0$ Hz, 1H), 7.61 (t, $J = 8.1$ Hz, 1H), 7.51 (d, $J = 7.8$ Hz, 1H), 4.32 (q, $J = 7.5$ Hz, 2H), 1.32 (t, $J = 7.0$ Hz, 3H);
APCI-MS m/z : 262.0 [MH^+].

10 Ethyl oxo{[3-(trifluoromethyl)-phenyl]amino}acetate (8.04 g, 30.7 mmol) was dissolved in ethanol (50 ml, 99.5%). To the stirred solution was added 1-amino-2-propanol (racemic, 2.32 g, 31 mmol) in one portion, and the mixture was heated to reflux for 90 minutes. The mixture was allowed to cool and was evaporated to dryness, giving N-(2-hydroxypropyl)-N'-(3-(trifluoromethyl)-phenyl)ethanediamide (8.80 g, 99%) as a white solid.

15 ^1H NMR (300 MHz, DMSO-d_6) δ 10.99 (bs, 1H), 8.77 (t, $J = 6.3$ Hz, 1H), 8.29 (s, 1H), 8.11 (d, $J = 8.2$ Hz, 1H), 7.60 (t, $J = 8.1$ Hz, 1H), 7.49 (d, $J = 7.5$ Hz, 1H), 4.91 (d, $J = 4.9$ Hz, 1H), 3.78 (p, $J = 5.7$ Hz, 1H), 3.20-3.12 (m, 2H), 1.05 (d, $J = 6.3$ Hz, 3H);
APCI-MS m/z : 273.1 [$\text{MH}^+ - 18$].

20 N-(2-Hydroxypropyl)-N'-(3-(trifluoromethyl)phenyl)-ethanediamide (2.2 g, 7.58 mmol) was dissolved in CH_3CN (50 ml) and water (7 ml). To the stirred solution was added NaBrO_3 (1.15 g, 7.58 mmol) and a solution of $\text{RuCl}_3\text{xH}_2\text{O}$ in CH_3CN (3 ml). The mixture was stirred for 1h, and the reaction was monitored by LC-MS and TLC. The organic solvent was removed in vacuo, and the residue was partitioned between DCM (200 ml) and water (200 ml). The organic phase was dried with Na_2SO_4 and upon filtration and evaporation N-(2-oxopropyl)-N'-(3-(trifluoromethyl)phenyl) ethanediamide (2.0 g, 91%) was obtained as a grey-white solid.

25 ^1H NMR (300 MHz, DMSO-d_6) δ 11.04 (s, 1H), 9.08 (t, $J = 6.0$ Hz, 1H), 8.29 (s, 1H), 8.12 (d, $J = 8.1$ Hz, 1H), 7.61 (t, $J = 8.1$ Hz, 1H), 7.50 (d, $J = 7.9$ Hz, 1H), 4.09 (d, $J = 6.0$ Hz, 2H), 2.14 (s, 3H).

N-(2-Oxopropyl)-N'-[3-(trifluoromethyl)phenyl] ethanediamide (1.6 g, 5.5 mmol) and glacial acetic acid (15 ml) were placed in a vial (20 ml). To this solution was added concentrated sulfuric acid (40 drops), and the flask was sealed, and heated with stirring to 5 100 °C for 90 minutes. Another 40 drops of sulfuric acid was added, and the reaction was allowed to proceed for another 90 minutes. The reaction mixture was allowed to cool, and acetic acid was removed in vacuo. The residue was partitioned between EtOAc (60 ml) and water (40 ml). The aqueous phase was neutralized by addition of NaOH solution to pH 6 to 10 7. The organic phase was dried, and upon filtration and evaporation a crude product was obtained, which was purified on silica giving 6-methyl-1-[3-(trifluoromethyl)phenyl]-1,4-dihdropyrazine-2,3-dione (1.1 g, 74%) as a yellowish solid.

¹H NMR (400 MHz, DMSO-d₆) δ 11.24 (bs, 1H), 7.87-7.81 (m, 2H), 7.77 (t, *J* = 7.8 Hz, 1H), 7.67 (d, *J* = 7.8 Hz, 1H), 6.30 (d, *J* = 5.2 Hz, 1H), 1.61 (d, *J* = 1.1 Hz, 3H); APCI-MS ^m/z: 271.0 [MH⁺].

15 6- Methyl-1-[3-(trifluoromethyl)phenyl]-1,4-dihdropyrazine-2,3-dione (0.52 g, 1.92 mmol) and 1,2-dichloroethane (10 ml) were placed in a vial (20 ml). To the resulting suspension was added carefully oxalyl bromide (0.53 ml, 1.24 g, 5.75 mmol). A foam was formed during the addition, and as the foam was settling down the stirring was started. 20 DMF (3 drops) was added and the vial was sealed and the mixture was stirred overnight. Another portion of oxalyl bromide (0.2 ml, 0.46 g, 2.23 mmol) and DMF (3 drops) were added and the reaction was run for another 24h. The mixture was partitioned between DCM (20 ml) and water (20 ml) and the organic phase was dried. Filtration and evaporation gave a crude product, which was purified on silica, affording 3-bromo-6- 25 methyl-1-[3-(trifluoromethyl)phenyl]pyrazin-2(1H)-one (0.59 g, 93%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.96 (s, 1H), 7.92 (d, *J* = 7.5 Hz, 1H), 7.83 (t, *J* = 7.5 Hz, 1H), 7.77 (d, *J* = 7.5 Hz, 1H), 7.27 (s, 1H), 1.84 (s, 3H); APCI-MS ^m/z: 232.9 and 234.9 [MH⁺].

30 A high-pressure steel reactor (Parr) with CO-gas inlet was charged with 3-bromo-6-methyl-1-[3-(trifluoromethyl)phenyl]pyrazin-2(1H)-one (0.25 g, 0.75 mmol), Pd(OAc)₂

(0.015 g, 0.067 mmol), PPh_3 (0.030 g, 0.11 mmol) and methanol (25 ml). To this mixture was added triethylamine (0.5 ml, 0.36 g, 3.6 mmol), and a magnetic stirrer bar. The reactor was ventilated with CO , and 6 atmospheres CO -pressure was applied to the system. The reactor was heated with stirring to 90 °C, and the mixture was stirred vigorously and the reaction was allowed to proceed for 4h. The volatiles were removed in *vacuo* and the crude product was purified on silica, to give methyl 5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylate (0.11 g, 47%) as a solid.

^1H NMR (400 MHz, DMSO-d_6) δ 7.97 (s, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.83 (t, J = 7.5 Hz, 1H), 7.77 (d, J = 7.5 Hz, 1H), 7.52 (s, 1H), 3.80 (s, 3H), 1.94 (s, 3H);
APCI-MS m/z : 313.0 [MH^+].

Methyl 5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylate (1.5 g, 4.8 mmol), dry DCM (7.0 mL), TFA (3.0 mL) and *N*-iodosuccinimide (1.0 g, 4.5 mmol) were mixed and stirred at RT in the dark (flask covered with aluminum foil). After 5h, water (5 mL) was added and the mixture was concentrated by rotary evaporation. Water (3 mL) was added once more and the mixture was concentrated as described above. The resulting mixture was diluted with acetonitrile to a total volume of 50 mL. Purification by preparative HPLC with acetonitrile-water as eluent (neutral eluent) gave methyl 6-iodo-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylate (0.905 g, 46%) as a yellow crystalline solid.

^1H NMR (400 MHz, DMSO-d_6) δ 7.93 (br s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.84 (t, J = 7.6 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 3.82 (s, 3H), 2.14 (s, 3H).
APCI-MS m/z 438.8 (MH^+).

25

Starting material SM2

Methyl 6-bromo-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylate

30 The title compound was prepared as described for the iodo analogue, SM1, but using *N*-bromo succinimide in DMF in the halogenation step.

¹H NMR (300 MHz, CDCl₃) δ 7.83 (d, *J* = 8.4 Hz, 1H), 7.75 (t, *J* = 8.4 Hz, 1H), 7.49 (br s, 1H), 7.41 (d, *J* = 8.4 Hz, 1H), 3.97 (s, 3H), 2.24 (s, 3H) ppm.

APCI-MS *m/z* 391, 393 [MH⁺].

5

Human Neutrophil Elastase Quenched-FRET Assay


The assay uses Human Neutrophil Elastase (HNE) purified from serum (Calbiochem art. 324681; Ref. Baugh, R.J. et al., 1976, Biochemistry. 15, 836-841). HNE was stored in 10 50 mM sodium acetate (NaOAc), 200 mM sodium chloride (NaCl), pH 5.5 with added 30% glycerol at -20 °C. The protease substrate used was Elastase Substrate V Fluorogenic, MeOSuc-AAPV-AMC (Calbiochem art. 324740; Ref. Castillo, M.J. et al., 1979, Anal. Biochem. 99, 53-64). The substrate was stored in dimethyl sulphoxide (DMSO) at -20 °C. The assay additions were as follows: Test compounds and controls were added to black 96- 15 well flat-bottom plates (Greiner 655076), 1 μL in 100% DMSO, followed by 30 μL HNE in assay buffer with 0.01% Triton (trade mark) X-100 detergent. The assay buffer constitution was: 100 mM Tris(hydroxymethyl)aminomethane (TRIS) (pH 7.5) and 500 mM NaCl. The enzyme and the compounds were incubated at room temperature for 15 minutes. Then 30 μL substrate in assay buffer was added. The assay was incubated for 30 20 minutes at room temperature. The concentrations of HNE enzyme and substrate during the incubation were 1.7 nM and 100 μM, respectively. The assay was then stopped by adding 60 μL stop solution (140 mM acetic acid, 200 mM sodium monochloroacetate, 60 mM sodium acetate, pH 4.3). Fluorescence was measured on a Wallac 1420 Victor 2 instrument at settings: Excitation 380 nm, Emission 460 nm. IC₅₀ values were determined 25 using Xlfit curve fitting using model 205.

When tested in the above screen, the compounds of the Examples gave IC₅₀ values for inhibition of human neutrophil elastase activity of less than 30 μM (micromolar), indicating that the compounds of the invention are expected to possess useful therapeutic 30 properties. Specimen results are shown in the following Table:

Compound	Inhibition of Human Neutrophil Elastase IC ₅₀ (nanomolar, nM)
Example 1	0.7
Example 2	2.3
Example 3	7.4
Example 4	9.5

C L A I M S

1. A compound of formula (I)



5 (I)

wherein

R¹ represents hydrogen or C₁-C₆ alkyl;

10 W represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; and wherein the phenyl or heteroaromatic ring is optionally substituted by at least one substituent selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, CN, OH, NO₂, C₁-C₃ alkyl substituted by one or more F atoms, C₁-C₃ alkoxy substituted by one or more F atoms, NR¹⁰R¹¹, C≡CR¹⁵, CONR¹⁶R¹⁷, CHO, C₂-C₄ alkanoyl, S(O)_xR¹⁸ and
 15 OSO₂R¹⁹;

20 R¹⁴ represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted in the 4- (para) position with F, Cl, CN or CF₃;

R¹⁰, R¹¹, R¹² and R¹³ independently represent H, C₁-C₆ alkyl, formyl or C₂-C₆ alkanoyl; or the group -NR¹⁰R¹¹ or -NR¹²R¹³ together represents a 5 to 7 membered

azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR²⁶;

R¹⁵ and R³⁰ independently represent H, C₁-C₃ alkyl or Si(CH₃)₃;

5

R¹⁸, R¹⁹, R³³ and R³⁴ independently represent H or C₁-C₃ alkyl; said alkyl being optionally substituted by one or more F atoms;

10 R³ represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said ring being optionally substituted with at least one substituent selected from halogen, C₁-C₆ alkyl, cyano, C₁-C₆ alkoxy, nitro, methylcarbonyl, NR³⁵R³⁶, C₁-C₃ alkyl substituted by one or more F atoms or C₁-C₃ alkoxy substituted by one or more F atoms;

15 R³⁵ and R³⁶ independently represent H or C₁-C₃ alkyl; said alkyl being optionally further substituted by one or more F atoms;

20 R⁴ represents hydrogen or C₁-C₆ alkyl optionally substituted with at least one substituent selected from fluoro, hydroxyl and C₁-C₆ alkoxy;

25 X represents a single bond, O, NR²⁴ or a group -C₁-C₆ alkylene-Y-, wherein Y represents a single bond, oxygen atom, NR²⁴ or S(O)_w; and said alkylene being optionally further substituted by OH, halogen, CN, NR³⁷R³⁸, C₁-C₃ alkoxy, CONR³⁹R⁴⁰, CO₂R⁶⁶, SO₂R⁴¹ and SO₂NR⁴²R⁴³;

25 or R⁴ and X are joined together such that the group -NR⁴X together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from

O, S and NR⁴⁴; said ring being optionally substituted by C₁-C₆ alkyl or NR⁴⁵R⁴⁶; said alkyl being optionally further substituted by OH;

either R⁵ represents a monocyclic ring system selected from

- 5 i) phenoxy,
- ii) phenyl,
- iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur,
- iv) a saturated or partially unsaturated C₃-C₆ cycloalkyl ring, or
- 10 v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at least one ring heteroatom selected from oxygen, S(O)_r and NR²⁰, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group,

or R⁵ represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)_t or C₁-C₆ alkylene optionally comprising one or more internal or terminal heteroatoms selected from oxygen, sulphur and NR²⁷ and being optionally substituted by at least one substituent selected from

20 hydroxyl, oxo and C₁-C₆ alkoxy,

the monocyclic or bicyclic ring system being optionally substituted by at least one substituent selected from oxygen, CN, OH, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, NR⁴⁷R⁴⁸, NO₂, OSO₂R⁴⁹, CO₂R⁵⁰, C(=NH)NH₂, C(O)NR⁵¹R⁵², C(S)NR⁵³R⁵⁴, SC(=NH)NH₂, NR⁵⁵C(=NH)NH₂, S(O)_vR²¹, SO₂NR⁵⁶R⁵⁷, C₁-C₃ alkoxy substituted by one or more F atoms and C₁-C₃ alkyl substituted by SO₂R⁵⁸ or by one or more F atoms; said C₁-C₆ alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio and -C(O)NR²²R²³;

or R^5 may also represent H;

R^{20} represents hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylcarbonyl or
5 C₁-C₆ alkoxy carbonyl;

R^{21} represents hydrogen, C₁-C₆ alkyl or C₃-C₈ cycloalkyl; said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, C₁-C₃ alkoxy and CONR⁵⁹R⁶⁰;

10

R^{37} and R^{38} independently represent H, C₁-C₆ alkyl, formyl or C₂-C₆ alkanoyl;

R^{47} and R^{48} independently represent H, C₁-C₆ alkyl, formyl, C₂-C₆ alkanoyl, S(O)_qR⁶¹ or SO₂NR⁶²R⁶³; said alkyl group being optionally further substituted by
15 halogen, CN, C₁-C₄ alkoxy or CONR⁶⁴R⁶⁵;

R^{41} and R^{61} independently represent H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

p is 0, 1 or 2;

20

q is 0, 1 or 2;

r is 0, 1 or 2;

t is 0, 1 or 2;

w is 0, 1 or 2;

x is 0, 1 or 2;

25

v is 0, 1 or 2;

$R^{16}, R^{17}, R^{22}, R^{23}, R^{24}, R^{26}, R^{27}, R^{31}, R^{32}, R^{39}, R^{40}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{49}, R^{50}, R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{56}, R^{57}, R^{58}, R^{59}, R^{60}, R^{62}, R^{63}, R^{64}, R^{65}$ and R^{66}
each independently represent hydrogen or C₁-C₆ alkyl;

5 or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1, wherein the group R^{14} and the pyrazinone ring are bonded to the phenyl or heteroaromatic ring W in a 1,2-relationship.

10 3. A compound according to Claim 1 or Claim 2, wherein R^3 represents a phenyl group substituted with one or two substituents independently selected from F, Cl, CN, NO₂ and CF₃.

15 4. A compound according to any one of Claims 1 to 3, wherein R^{14} represents a phenyl or pyridinyl group substituted in the 4- (para) position with F, Cl or CN.

5. A compound according to any one of Claims 1 to 4, wherein X represents C₁-C₂ alkylene, optionally substituted by OH, halogen, CN, CO₂R⁶⁶ or C₁-C₃ alkoxy.

20 6. A compound according to any one of Claims 1 to 4, wherein X represents a single bond.

7. A compound according to any one of Claims 1 to 6, wherein R^5 represents H.

25 8. A compound of formula (I) as defined in Claim 1 selected from:

N-((6-(4'-cyanobiphenyl-2-yl)-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazin-2-yl)carbonyl)glycine;

3'-(4-cyanophenyl)-3-methyl-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-2,2'-bipyrazine-6-carboxamide;


6-[4-(4-cyanophenyl)pyrimidin-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxamide;

5 6-[2-(4-cyanophenyl)pyridin-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihdropyrazine-2-carboxamide;

and pharmaceutically acceptable salts of any one thereof.

9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 which comprises,


10 (a) reacting a compound of formula (II)



(II)


wherein L^1 represents a leaving group (such as halogen or hydroxyl) and R^1 , R^3 , R^{14} and W are as defined in formula (I),

15 with a compound of formula



wherein X , R^4 and R^5 are as defined in formula (I); or

20 (b) reacting a compound of formula (IV)




(IV)

wherein Hal represents a halogen atom and X, R¹, R³, R⁴ and R⁵ are as defined in formula (I),

with a nucleophile R¹⁴-W-M wherein R¹⁴ and W are as defined in formula (I) and M represents an organo-tin or organo boronic acid group; or

(c) reacting a compound of formula (V)



(V)

wherein Hal represents a halogen atom and W, X, R¹, R³, R⁴ and R⁵ are as defined in formula (I),

with a nucleophile R¹⁴-M wherein R¹⁴ is as defined in formula (I) and M represents an organo-tin or organo boronic acid group;

and optionally after (a), (b) or (c) carrying out one or more of the following:

- 15 • converting the compound obtained to a further compound of the invention
- forming a pharmaceutically acceptable salt of the compound.

10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 5 11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 10 12. A compound of formula (I) or a pharmaceutically-acceptable salt thereof as claimed in any one of claims 1 to 8 for use in therapy.
- 15 13. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of neutrophil elastase activity is beneficial.
- 20 14. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury.
- 25 15. A method of treating, or reducing the risk of, a disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8.

16. A method of treating, or reducing the risk of, an inflammatory disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8.

5

17. A method according to Claim 15 or Claim 16, wherein the disease or condition is adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis,

10 ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2008/051220

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2007129963 A1 (ASTRAZENECA AB), 15 November 2007 (15.11.2007), claims, examples --	1-17
A	WO 2006098683 A1 (ASTRAZENECA AB), 21 Sept 2006 (21.09.2006), claims, examples --	1-17
A	WO 2005026123 A1 (ASTRAZENECA AB), 24 March 2005 (24.03.2005), claims, examples -----	1-17

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

2 February 2009

Date of mailing of the international search report

04-02-2009

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Solveig Gustavsson/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE2008/051220**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 15 - 17
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 15-17 relate to a method for treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2008/051220

Box II.2

methods, see PCT rule 39.1(iv). Nevertheless, a search has been made for these claims. The search has been directed to the technical content of the claims.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2008/051220

International patent classification (IPC)

C07D 241/24 (2006.01)
A61K 31/4965 (2006.01)
A61K 31/497 (2006.01)
A61K 31/506 (2006.01)
A61P 1/04 (2006.01)
A61P 11/00 (2006.01)
A61P 19/00 (2006.01)
C07D 401/04 (2006.01)
C07D 403/04 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded at www.prv.se by following the links:

- In English/Searches and advisory services/Cited documents (service in English) or
- e-tjänster/anfördra dokument(service in Swedish) .

Use the application number as username.

The password is **LGZPPZAOIU**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85) .

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/11/2008

International application No.
PCT/SE2008/051220

WO	2007129963	A1	15/11/2007	AR	060874 A	16/07/2008
				AU	2007248951 A	15/11/2007
				UY	30327 A	02/01/2008
-----	-----	-----	-----	-----	-----	-----
WO	2006098683	A1	21/09/2006	AR	053180 A	25/04/2007
				AU	2006223675 A	21/09/2006
				CA	2600038 A	21/09/2006
				CN	101142188 A	12/03/2008
				CN	101142189 A	12/03/2008
				EP	1861370 A	05/12/2007
				EP	1861371 A	05/12/2007
				JP	2008533136 T	21/08/2008
				JP	2008533137 T	21/08/2008
				KR	20070114154 A	29/11/2007
				NO	20075059 A	08/10/2007
				UY	29420 A	31/10/2006
				WO	2006098684 A	21/09/2006
-----	-----	-----	-----	-----	-----	-----
WO	2005026123	A1	24/03/2005	AU	2004272484 A,B	24/03/2005
				BR	PI0414548 A	07/11/2006
				CA	2538405 A	24/03/2005
				CN	1882542 A	20/12/2006
				EP	1663973 A	07/06/2006
				IS	8381 A	28/03/2006
				JP	2007505901 T	15/03/2007
				KR	20060087569 A	02/08/2006
				MX	PA06002724 A	06/06/2006
				NO	20061660 A	11/04/2006
				RU	2006112428 A	10/11/2007
				SE	0302486 D	00/00/0000
				US	20070203129 A	30/08/2007
					28514 A	29/04/2005
-----	-----	-----	-----	-----	-----	-----